VivoSeq
Other

Hypertrophy

25

Pipeline Programs↗

6

Active Trials↗

18

Companies Involved↗

Hypertrophy is an emerging landscape with 25 programs across 18 companies. The most active players are Bayer, Pfizer, Novo Nordisk. 6 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

7/100

Completion Rate

76/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 3EMD Serono logo

EMD Serono

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

27 of 29 classified programs — the dominant modality here.

7%ALL OTHERSPeptide13%Radiopharmaceutical13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed19 · 58%
Withdrawn4 · 12%
Active, not recruiting3 · 9%
Unknown status2 · 6%
Terminated2 · 6%
Not yet recruiting2 · 6%
Other1 · 3%

Clinical Trials

Trial Activity

33 trials

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05195710·50 enrolled
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Active, not recruiting·—·Phase 2·NCT04019197·108 enrolled
To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy
Active, not recruiting·HHuons Biopharma·Phase 3·NCT05964257·188 enrolled
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Active, not recruiting·SSwedish Orphan Biovitrum·Phase 4·NCT06752850·37 enrolled
Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery: A Prospective Randomized Controlled Trial
Not yet recruiting·SSun Yat-sen University·Preclinical·NCT07552545·138 enrolled
Erector Spinae Plane Block (ESPB) Versus Intravenous Lidocaine Infusion for Postoperative Pain and Quality of Recovery in Patients Undergoing Breast Reduction Surgery: A Single Center, Prospective, Randomized Study.
Not yet recruiting·CCentre of Postgraduate Medical Education·Preclinical·NCT07687069·80 enrolled
MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy
Completed·MMedy-Tox·Phase 3·NCT03452345·180 enrolled
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Completed·AAEterna Zentaris·Phase 3·NCT00663858·420 enrolled
Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy
Completed·UUniversity of Copenhagen·N/A·NCT02551276·42 enrolled
Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy
Completed·GGuangzhou Women and Children's Medical Center·Phase 4·NCT02559440·240 enrolled
A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy
Completed·UUniversity Hospital, Bordeaux·Phase 3·NCT01275521·127 enrolled
Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)
Completed·—·Phase 3·NCT00552032·132 enrolled
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)
Completed·NNorth Florida/South Georgia Veterans Health System·N/A·NCT00382356·20 enrolled
Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy
Completed·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 3·NCT04294251·180 enrolled
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
Completed·Bayer logoBayer·Phase 2·NCT00461123·50 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)